Inhibitors of DNA binding (IDs) antagonize basichelix-loop-helix (bHLH) transcription factors to inhibit differentiation and maintain stem cell fate. ID ubiquitination and proteasomal degradation occur in differentiated tissues, but IDs in many neoplasms appear to escape degradation. We show that the deubiquitinating enzyme USP1 promotes ID protein stability and stem cell-like characteristics in osteosarcoma. USP1 bound, deubiquitinated, and thereby stabilized ID1, ID2, and ID3. A subset of primary human osteosarcomas coordinately overexpressed USP1 and ID proteins. USP1 knockdown in osteosarcoma cells precipitated ID protein destabilization, cell-cycle arrest, and osteogenic differentiation. Conversely, ectopic USP1 expression in mesenchymal stem cells stabilized ID proteins, inhibited osteoblastic differentiation, and enhanced proliferation. Consistent with USP1 functioning in normal mesenchymal stem cells, USP1-deficient mice were osteopenic. Our observations implicate USP1 in preservation of the stem cell state that characterizes osteosarcoma and identify USP1 as a target for differentiation therapy.
INTRODUCTION
Basic-helix-loop-helix (bHLH) transcription factors comprise the third-largest family of recognized transcription factors in the human genome (Tupler et al., 2001) and are essential regulators of development and differentiation through binding DNA elements termed E boxes (Massari and Murre, 2000) . Class I bHLH homodimers are expressed broadly and promote expression of antiproliferative genes such as CDKN1A, CDKN2A, and CDKN2B (Yokota and Mori, 2002) . Class II bHLH proteins show more restricted expression and form heterodimers with class I proteins to drive tissue-specific genes such as IGH@ and SP7/OSTERIX (Lassar et al., 1991; Weintraub et al., 1994) . Through the combined induction of tissue-specific and antiproliferative genes, bHLH transcription factors serve as integrators of lineage commitment.
DNA binding of bHLH proteins is limited by heterodimerization with inhibitor of DNA-binding proteins, or IDs. The ID family consists of four members, ID1, ID2, ID3, and ID4 (Lasorella et al., 2001) , with overlapping spatial and temporal expression profiles. All four IDs bind the various bHLH proteins with similar affinities to regulate gene expression (Prabhu et al., 1997) . IDs are essential for mammalian development; disruption of two or more ID genes results in embryonic lethality (Lyden et al., 1999) . In contrast, overexpression of ID proteins in transgenic mice produces fatal malignancies (Kim et al., 1999) . Similarly, elevated ID protein levels are observed in a broad range of dedifferentiated primary human malignancies ranging from pancreatic carcinoma to neuroblastoma (Perk et al., 2005) . Although ID proteins are scarce in normal adult differentiated tissues, they are abundant in proliferating tissues, including embryonic and adult stem cell populations, which suggests that IDs might maintain ''stemness'' (Yokota and Mori, 2002) . The stem cell expression and tumor-promoting qualities of ID proteins suggest that ID genes may be pivotal in cancer stem cell biology. An engineered ID-suppressing HLH protein was reported to differentiate neuroblastoma tumors (Ciarapica et al., 2009) .
IDs are induced transcriptionally by myriad growth factors including bone morphogenic proteins, platelet-derived growth factor, epidermal growth factor, as well as by T cell receptor ligation (Yokota and Mori, 2002) . ID1, ID2, and ID3, but not ID4, are subject to K48-linked polyubiquitination and subsequent degradation by the 26S proteasome. Consequently, IDs are short lived in most tissues (Bounpheng et al., 1999) . The ubiquitously expressed APC/Cdh1 complex is an E3 ubiquitin ligase that governs ID stability and abundance (Lasorella et al., 2006) , but ID proteins are stable in some contexts. Therefore, we sought a deubiquitinating enzyme that counters ID ubiquitination.
We show that USP1 deubiquitinates and stabilizes ID1, ID2, and ID3, resulting in their increased abundance. Significantly, elevated USP1 protein and mRNA in a subset of primary osteosarcoma tumors correlated with increased ID protein levels. USP1 knockdown in osteosarcoma cells caused ID protein destabilization, p53-independent induction of CDKN1A encoding cyclin-dependent kinase inhibitor (CDKI) p21, and cellcycle arrest. In addition, expression of mesenchymal stem cell markers was decreased and osteogenic differentiation resumed. These data suggest that osteosarcomas, like acute promyelocytic leukemia, may be amenable to differentiation therapies (Soignet et al., 1998) . In contrast to USP1 knockdown, USP1 overexpression in primary human mesenchymal stem cells (hMSCs) caused ID protein accumulation and interfered with normal differentiation. Indeed, USP1 promoted transformation in a mesenchymal cell line. Finally, loss of Usp1 in gene-targeted mice caused severe osteopenia, which is consistent with a role for USP1 in the mesenchymal lineage. Our results strongly suggest that USP1 has oncogenic potential and promotes tumorigenesis through disruption of normal mesenchymal stem cell commitment and differentiation.
RESULTS

USP1 Deubiquitinates and Stabilizes ID Proteins
To identify deubiquitinases (DUBs) that stabilize ID proteins, we overexpressed 94 human DUBs with C-terminal Flag epitopes in 293T cells and assessed endogenous ID2 abundance by western blot (see Table S1 available online). 293T cells degrade ID2 in a proteasome-dependent manner because ID2 accumulates after treatment with the proteasome inhibitor MG-132 ( Figure S1A ). DUBs that increased endogenous ID2 were USP36, JOSD2, USP33, SENP3, SENP5, USP37, OTUD5, USP9Y, USP45, and USP1 ( Figure S1A ). To exclude indirect mechanisms increasing ID2 expression, we focused on ID2-interacting DUBs USP1 and USP33 ( Figure S1B ). However, unlike USP1, USP33 lacked deubiquitinating activity against ID2 (data not shown).
To determine whether USP1 extended the half-life of ID2, we transfected 293T cells with USP1 and monitored ID2 abundance after treatment with the translational inhibitor cycloheximide. In the absence of new protein synthesis, ID2 was cleared rapidly from cells transfected with a control vector, with a half-life of approximately 2 min ( Figure 1A ). Overexpressed USP1 extended the half-life of ID2 to over 80 min. The proteolytic activity of USP1 was necessary for ID2 accumulation because the catalytically inactive point mutant USP1 C90S (Nijman et al., 2005) neither increased the half-life of ID2 ( Figure 1A ) nor altered ID2 steady-state abundance ( Figure 1B) . Similar results were obtained with ID1 and ID3. USP1 appeared to target IDs specifically because it did not enhance expression of labile IkBa (Palombella et al., 1994) .
Next, we assessed the effect of USP1 on ID2 ubiquitination. Wild-type USP1, but not USP1 C90S, reduced the amount of ID2 modified with HA-tagged ubiquitin ( Figure 1C ). Both basal and USP1-induced ID2 deubiquitination was enhanced by coexpression of USP1 cofactor WDR48 (Cohn et al., 2007) (Figure 1C ). To address whether USP1 deubiquitinated ID2 directly, ubiquitinated ID2 purified from 293T cells was incubated in vitro with either wild-type USP1 or USP1 C90S purified separately from 293T cells. Ubiquitinated ID2 was decreased by wild-type USP1 but not USP1 C90S ( Figure 1D ), indicating that deubiquitination was unlikely a consequence of a coeluted protease. The decrease in ID2 ubiquitination also was sensitive to N-ethylmaleimide, confirming the involvement of a cysteine protease ( Figure 1D ). Consistent with ubiquitinated ID2 being a USP1 substrate, deletion mutant USP1D260-300 interacted poorly with ID2 ( Figure S1C ) and did not enhance ID2 abundance ( Figure S1D ).
USP1 and ID2 Are Coordinately Overexpressed in a Subset of Primary Osteosarcoma Tumors
To identify a biological context in which USP1 deubiquitinates ID proteins, we examined USP1 expression patterns. Microarray analyses of healthy and diseased human tissues revealed that osteosarcoma tumors expressed more USP1 mRNA than healthy or osteoarthritic bone biopsies ( Figure 2A ). Western blotting of a separate set of primary human osteosarcoma biopsies found that USP1 was elevated in 7 of 14 osteosarcomas when compared to 3 normal primary human osteoblast samples (Figure 2B) . Strikingly, ID2 protein abundance in these primary human tumor samples correlated well with USP1 abundance. One anomalous sample contained abundant USP1 but little ID2 ( Figure 2B , lane 6), perhaps due to poor expression of the USP1 cofactor WDR48. Another sample contained abundant ID2 and little USP1 ( Figure 2B , lane 16), which may reflect reduced ID2 ubiquitination or that other DUBs are active.
The amount of USP1 protein in the primary osteosarcomas correlated largely with USP1 mRNA abundance ( Figure 2C ), suggesting that elevated USP1 in osteosarcoma is due to transcriptional upregulation. In contrast, ID2 protein and mRNA levels correlated poorly ( Figure 2D ). The coincident overexpression of USP1 and ID2 in primary osteosarcoma was confirmed by immunohistochemistry ( Figures 2E-2G ). These results strongly suggest that USP1 modifies ID proteins posttranslationally in osteosarcoma.
USP1 Stabilizes ID Proteins in Osteosarcoma
We also assessed USP1 abundance and ID2 stability in human osteosarcoma cell lines and in primary osteoblasts ( Figure S2A ). In U2-OS osteosarcoma cells, USP1 was elevated, and the normally labile ID2 was stable ( Figures S2A and S2B) . Knockdown of USP1 with two distinct USP1 shRNAs caused a reduction in ID1, ID2, and ID3 but had no effect on ID4 ( Figure 3A) . ID1, ID2, and ID3 mRNAs were not reduced, excluding decreased transcription as the reason for the drop in ID protein abundance (Figure S3I ). USP1 knockdown specificity was confirmed with shRNA-resistant USP1, which restored ID1, ID2, and ID3 to basal levels. USP1 catalytic activity was essential for ID stability because shRNA-resistant USP1 C90S did not restore ID protein levels. Similar results were observed in osteosarcoma cell lines HOS, SAOS, and SJSA ( Figure S2C ). USP1 knockdown did not impact ID2 abundance in MG-63 osteosarcoma cells, likely because these cells express very little WDR48 ( Figure S2C ). Consistent with WDR48 deficiency limiting USP1 activity in MG-63 cells, ectopic WDR48 increased ID2 ( Figure S2D ).
To determine if USP1 knockdown and decreased IDs 1-3 modulated bHLH transcriptional activity, U2-OS cells were transfected with an E box-driven luciferase reporter gene. USP1 shRNAs enhanced expression of this reporter 7-to 10-fold over a control shRNA, consistent with activation of bHLH proteins when ID proteins are decreased ( Figure 3B ). shRNA-resistant wild-type USP1, but not USP1 C90S, suppressed E box-driven reporter activity caused by USP1 knockdown, confirming that USP1 catalytic activity is required for bHLH-dependent transcription as well as ID protein stabilization.
The acute loss of IDs 1-3 following knockdown of endogenous USP1 suggested ID protein destabilization via proteasomemediated degradation. As anticipated, the proteasome inhibitor MG-132 did not by itself alter ID protein abundance in U2-OS cells, suggesting that the IDs are intrinsically stable in cells that express USP1 highly ( Figure 3C ). However, MG-132 treatment did restore ID expression after USP1 knockdown, indicating that ID proteins are subject to proteasome-mediated clearance upon USP1 depletion. In keeping with this scenario, USP1 knockdown in MG-132-treated U2-OS cells increased the amount of ubiquitinated ID2 ( Figure 3D ).
Next, we confirmed that endogenous USP1 associates with an endogenous ID in osteosarcoma cells. ID2 coimmunoprecipitated with endogenous USP1 from U2-OS cells ( Figure 3E ), albeit not with 1:1 stoichiometry, but this is to be expected for a transient enzyme-substrate interaction. Similar results were obtained in HOS cells ( Figure S2E ). USP1 also coimmunoprecipitated with ID2 ( Figure 3F ). Collectively, our results suggest that USP1 is a potent DUB and stabilizing factor for ID1, ID2, and ID3 in osteosarcoma. ID2 stabilization by USP1 was not limited to the setting of osteosarcoma. USP1 À/À DT40 chicken B cells (Oestergaard et al., 2007) expressed less ID2 protein than their wild-type counterparts ( Figure S2F ) despite expressing similar levels of ID2 mRNA ( Figure S2G ). Consistent with USP1 deubiquitinating and stabilizing ID2, proteasome inhibition with MG-132 increased ID2 in USP1 À/À , but not wild-type, DT40 cells (Figure S2H) . In addition, USP1 À/À DT40 cells reconstituted with wild-type USP1, but not USP1 C90S, contained equivalent ID2 to wild-type DT40 cells ( Figure S2I ).
USP1 Suppresses p21-Mediated Cell-Cycle Arrest in Osteosarcoma
One potential consequence of USP1 deficiency and increased bHLH transcriptional activity in osteosarcoma cells is induction of bHLH-regulated CDKI p21. Indeed, p21 was increased in U2-OS cells transfected with USP1 shRNAs relative to cells transfected with a control shRNA ( Figure 4A ). shRNA-resistant wild-type USP1, but not USP1 C90S, reduced p21 to levels observed in control cells, confirming knockdown specificity in this setting. The tumor suppressor p53, a well-known inducer of CDKN1A, was not increased by USP1 knockdown, suggesting that increased p21 was p53 independent. p21 is a potent inhibitor of cell cycle progression (Polyak et al., 1996) , so we assessed the proliferative capacity of U2-OS cells following USP1 knockdown. Consistent with increased p21, USP1 knockdown reduced U2-OS cell proliferation ( Figure 4B and Figure S3A ). shRNA-resistant wild-type USP1, but neither USP1 C90S nor USP1D260-300, restored cell proliferation ( Figures S3B and S3C ), indicating that both USP1 catalytic activity and ID substrate recognition are required to maintain U2-OS cell proliferation. USP1 knockdown similarly reduced proliferation in HOS, SAOS, and SJSA, but not MG-63 osteosarcoma cells (Figure S3D) . Flow cytometric analysis of the DNA content in U2-OS cells after USP1 knockdown revealed a moderate increase in cells in G1 and G2 phases of the cell cycle with a pronounced reduction of cells in S phase ( Figure 4C and Figure S3E ). Apoptosis induction following USP1 knockdown was not prominent; few cells with a subdiploid DNA content were observed, there was no increase in cells stained with annexin V, and increased processing of caspase-3 was not detected ( Figure S3E ; data not shown). Significantly, CDKN1A siRNAs restored S phase entry in USP1-deficient U2-OS cells (Figure S3F and S3G) , indicating that p21 is essential for the cell-cycle arrest induced by USP1 knockdown.
USP1 Regulates p21 Expression and Cell-Cycle Arrest in Osteosarcoma via ID Proteins
If ID degradation in the absence of USP1 caused p21 induction, then knockdown of the ID proteins should phenocopy USP1 knockdown. shRNA knockdown of IDs 1-3 individually did not alter p21 levels, but combined knockdown of ID1, ID2, and ID3 increased p21 similar to USP1 knockdown ( Figure S3H ). IDand USP1-deficient cells also expressed comparable levels of CDKN1A mRNA ( Figure S3I ). Consistent with these observations, ID deficiency caused cell-cycle arrest similar to USP1 deficiency ( Figures S3J and S3K) , and this was rescued by p21 knockdown (Figures 4D and 4E) . CDKN1A is regulated by many transcription factors, including p53, which is activated in response to DNA damage (Kastan et al., 1991) . p53 knockdown inhibited etoposide-induced p21 in U2-OS cells but did not block the increase in p21 protein seen after USP1 knockdown ( Figure S3L ), supporting a p53-independent mechanism of p21 induction. Because USP1 is reported to target PCNA and FANCD2 during DNA repair (Nijman et al., 2005; Huang et al., 2006) , we also checked if USP1 knockdown produced DNA damage. H2AX phosphorylation that is associated with DNA damage (Rogakou et al., 1999) increased after etoposide treatment but not USP1 knockdown (data not shown). These observations, combined with the ability of USP1 shRNAs to arrest p53-deficient SAOS cells ( Figure S3D ), exclude general DNA damage, and p53 in particular, as intermediaries in p21 induction following USP1 knockdown.
We confirmed that USP1 regulates p21 expression and cell cycling via the IDs by rescuing the effects of USP1 knockdown in U2-OS cells with ectopic expression of ID1, ID2, and ID3. ID expression in USP1-depleted cells inhibited p21 expression ( Figure 4F ) and blocked cell-cycle arrest ( Figure 4G ). Taken together, our results demonstrate that USP1 suppresses p21 via ID protein stabilization and inhibition of bHLH transcriptional activity in osteosarcoma.
USP1 and ID Proteins Restrict Osteogenic Commitment in Osteosarcoma
Osteosarcomas are heterogeneous tumors comprised of disorganized masses of osteoblasts, chondrocytes, and adipocytes. These tumors are thought to develop from a mesenchymal stem cell population that can give rise to all three lineages . Accordingly, osteosarcoma cell lines fail to express classical osteoblast markers such as RUNX2, OSTERIX, SPARC/ OSTEONECTIN, and alkaline phosphatase (ALP) . Osteosarcoma cell lines also express surface markers characteristic of mesenchymal stem cells, including CD90, CD105, and CD106 (Di Fiore et al., 2009) . In light of the role that IDs play in stem cell maintenance and regulation of differentiation, we investigated whether either USP1 or ID knockdown in osteosarcoma would trigger osteoblastic differentiation. U2-OS cells transfected with USP1 or ID shRNAs expressed less CD105, CD106, and CD90 relative to control cells, whereas all cells expressed equivalent amounts of the unrelated surface marker CD144 ( Figure S4A ). Similar results were observed with HOS, SJSA, and SAOS cell lines. USP1 or ID knockdown also increased expression of osteoblastic RUNX2, OSTERIX, and OSTEONECTIN ( Figure S4B ), and increased ALP activity ( Figure S4C) . Increased E-cadherin expression and reduced N-cadherin and fibronectin following USP1 knockdown in U2-OS cells indicated a reversal of the epithelial to mesenchymal transition that accompanies the malignant state of osteosarcoma ( Figures 5A and 5B) (Thiery et al., 2009 ). Collectively, these data suggest that ID protein stabilization by USP1 in osteosarcoma blocks a normal osteogenic differentiation program.
The potential of USP1 inhibition as a tumor differentiation strategy was investigated in the 143B osteosarcoma xenograft model. A doxycycline-induced USP1 shRNA suppressed USP1 expression and reduced ID1 and ID2 in the xenografts ( Figure 5C and Figure S4D ). ID3 was not detectable in this setting (data not shown). USP1 knockdown also reduced 143B tumor growth ( Figure 5D ), promoted OSTEONECTIN, RUNX2, SPP1/ OSTEOPONTIN, OSTERIX, and BGLAP/OSTEOCALCIN expression ( Figure 5E and Figure S4E ), and enhanced ALP activity ( Figure 5F ). Remarkably, four of ten USP1-deficient xenograft tumors achieved stasis and differentiation in situ, displaying markedly altered cellular morphology and accumulation of acellular collagenous masses consistent with proto-ossification ( Figure 5G ). The tumors that continued to proliferate showed evidence of escape from knockdown, presumably due to loss or silencing of the shRNA ( Figure S4F ). These data indicate that reducing USP1 is sufficient to initiate an osteogenic differentiation program in osteosarcoma.
Dysregulated USP1 Expression Inhibits hMSC Differentiation
Next, we determined if USP1 stabilization of the IDs contributes to normal mesenchymal stem cell maintenance. USP1 was expressed in primary hMSCs but declined steadily as the cells were cultured in conditions favoring osteoblastic differentiation ( Figure 6A ). Consistent with a previous study (Peng et al., 2003) , ID1 and ID2 were induced transiently and then declined as well. ID3 was not detected (data not shown). These data, together with a study showing that misregulated ID expression inhibits osteogenic differentiation (Peng et al., 2004) , prompted us to investigate whether USP1 overexpression disrupts hMSC differentiation. hMSCs overexpressing USP1 and cultured in osteogenic differentiation medium expressed abnormally high levels of ID1 and ID2 ( Figure 6B ), exhibited low ALP activity (Figure 6C) , showed minimal induction of RUNX2, OSTERIX, and OSTEONECTIN ( Figure 6D ), and stained poorly with alizarin red, which reveals mineral deposition that is a classic marker of osteoblast activity ( Figure 6E ). These data imply that the hMSCs overexpressing USP1 failed to differentiate. A similar differentiation defect was observed in hMSCs overexpressing ID2, whereas hMSCs overexpressing USP1 C90S differentiated similarly to control cells. Thus, the catalytic activity of USP1 was necessary and ID stabilization sufficient to inhibit osteogenic differentiation.
Coincident with their apparent failure to differentiate, hMSCs overexpressing USP1 or ID2 proliferated significantly in the presence of excess osteogenic differentiation factors ( Figure 6F ). In contrast, proliferation of control hMSCs, or those expressing USP1 C90S, slowed as they differentiated in culture. Collectively, our observations suggest that overexpression of USP1 or ID2 is sufficient to block osteoblastic differentiation, promote retention of stem-like features, and render cells resistant to differentiation cues.
USP1 Promotes Transformation and Tumor Formation
The ability of USP1 to inhibit mesenchymal stem cell differentiation and sustain proliferation of osteosarcoma cell lines suggested that USP1 might promote cell transformation. We explored this possibility with NIH 3T3 cells stably transduced with empty vector, ID2, USP1, or USP1 C90S. Wild-type USP1 increased expression of IDs 1-3 ( Figure S5A ) and caused anchorage-independent cell proliferation in soft agar (Figure S5B ), which is a classic hallmark of oncogenic transformation (Hanahan and Weinberg, 2000) . In contrast, cells transduced with empty vector or USP1 C90S did not grow well in soft agar ( Figures S5B and S5C) . Interestingly, USP1 produced larger and more numerous colonies than ID2 ( Figure S5C ), suggesting that stabilization of multiple ID proteins may be more transforming than ID2 overexpression alone.
Our in vitro observations were recapitulated in vivo when NIH 3T3 cells were implanted subcutaneously into C.B-17 SCID.bg mice. Control cells and cells expressing USP1 C90S failed to produce measurable tumors, whereas cells overexpressing USP1 or ID2 produced measurable tumors as early as 7 days postimplantation ( Figure S5D ). Gross visual inspection of tumors at the study endpoint confirmed that cells overexpressing USP1 or ID2 produced aggressive malignancies ( Figure S5E ). Similar results were observed in NCr nude mice.
We assessed the contribution of the IDs to NIH 3T3 cell transformation by USP1 with Id1, Id2, and Id3 shRNAs. Suppression of IDs 1-3 ( Figure S5F ) blocked colony formation in soft agar ( Figure S5G ), indicating that the IDs are essential for USP1 transformation of NIH 3T3 cells.
USP1 Regulates Bone Development
Because USP1 overexpression impaired osteoblastic differentiation of mesenchymal precursors, whereas USP1 loss caused osteoblastic differentiation of osteosarcoma cells, we investigated whether USP1 regulates normal bone development with Usp1 gene-targeted mice. P12 Usp1 À/À mice were osteopenic with defects in ossification of the cranial and long bones (Figure 7A ). Underdeveloped sternal ribs likely contribute to the lethal cyanotic respiratory failure in Usp1 À/À pups (Kim et al., 
2009). Bone mineral density and volume in Usp1
À/À neonates and E18.5 embryos were much less than in wild-type littermates (Figures 7B and 7C and Figures S6B and S6C) . Neither FANCD2-nor PCNA-deficient mice exhibit perinatal lethality (Parmar et al., 2010; Roa et al., 2008) , excluding destabilization of these USP1 substrates as the primary cause of the perinatal lethality associated with USP1 deficiency. Usp1 À/À and Usp1 +/+ femurs contained similar numbers of resting, transitional, proliferating, and hypertrophic chondrocytes, but deposition of osteoid on emergent bone spicules was diminished, suggesting reduced activity of osteoid-depositing osteoblasts (Figures S6D-S6F ). Consistent with a defect in osteoblast function, serum levels of bone alkaline phosphatase (BALP), a marker of systemic osteoblast activity, were reduced in Usp1 À/À E18.5 embryos ( Figure 7E ). USP1 deficiency did not alter osteoclast abundance or activity ( Figures S6G-S6I ), excluding increased bone resorption in the Usp1 À/À mice. Significantly, and in keeping with observations made in osteosarcoma and mesenchymal stem cell cultures, Usp1 À/À femoral metaphyses contained less ID1 and ID2 than their wild-type counterparts ( Figure 7D and Figure S6J ). These data indicate that the USP1-ID axis regulating differentiation in osteosarcoma is recapitulated in normal skeletal development.
DISCUSSION
In this study we show that ID stabilization by USP1 sustains a significant fraction of human osteosarcomas. USP1 was overexpressed frequently in primary osteosarcomas and osteosarcoma cell lines (Figure 2) , and by deubiquitinating the ID proteins (Figures 1 and 3) , inhibited bHLH-dependent expression of CDKI p21 (Figure 4 ) resulting in unchecked cell proliferation ( Figure 5 ). USP1 overexpression not only was necessary for the proliferation of several osteosarcoma cell lines, it also was sufficient to prevent normal mesenchymal cell differentiation, capturing the cells in a stem-like state ( Figure 6 ). By contrast, USP1 knockdown in osteosarcoma cell lines reduced expression of mesenchymal stem cell markers and initiated an osteogenic development program ( Figure 5 ). USP1 deficiency in mice impaired normal osteogenesis and resulted in pronounced osteopenia (Figure 7) . Therefore, we posit that overexpressed USP1 interferes with mesenchymal stem cell differentiation and thereby fosters the development of malignant mesenchymal cell populations.
USP1 Is an ID DUB Overexpressed in Osteosarcoma
Our screen for DUBs capable of stabilizing ID2 ( Figure S1 ) identified both USP1 and USP33, although USP33 was unable to deubiquitinate ID2 (data not shown). USP33 binding ID2 may have precluded ID2 recognition by the proteasome and prevented its degradation. Other DUBs that enhanced ID2 expression in our screen did not appear to interact with ID2 and must influence ID2 abundance indirectly. These DUBs may upregulate ID gene expression, interfere with the ubiquitinconjugation machinery, or otherwise impair proteasome function. For example USP9X may upregulate ID2 gene expression by deubiquitinating and stabilizing the transcription factor SMAD4 (Dupont et al., 2009) .
The mechanism responsible for USP1 overexpression in a subset of osteosarcomas (Figure 2 ) is unclear. USP1 mRNA and protein levels correlated strongly implying transcriptional upregulation. Notably, recent CGH analyses found that the USP1 locus 1p31.3 was amplified in 26%-57% of osteosarcoma tumors (Ozaki et al., 2003; Stock et al., 2000) .
USP1 Promotes Proliferation via ID-Mediated Repression of CDKI p21
We show that ID protein stabilization by USP1 disrupts bHLHdependent p21 expression in osteosarcoma (Figure 4 and Figure S3 ). Thus, USP1 overexpression perturbs normal osteoblast differentiation, which is characterized by p53-independent upregulation of multiple CDKIs (Funato et al., 2001; Kenner et al., 2004; Matsumoto et al., 1998; Yan et al., 1997; Zhang et al., 1997) . CDKI function often is compromised in osteosarcomas; CDKN2A/p16 INK4a and CDKN2B/p15 INK4b gene deletions are common (Miller et al., 1996; Nielsen et al., 1998) , as is gene inactivation due to promoter methylation (Oh et al., 2006) . In contrast, CDK4, a target of CDKIs, is frequently overexpressed in osteosarcoma due to gene amplification (Ozaki et al., 2003) . ID-mediated transcriptional repression of p21 represents an additional oncogenic mechanism in osteosarcoma. ID protein overexpression has been observed in various human cancers but has been attributed largely to increased ID transcription (Perk et al., 2005) . For example ID2 is transcriptionally upregulated by the EWS-Ets translocation in Ewing's sarcoma (Nishimori et al., 2002) , which is an osteoid tumor bearing strong resemblance to osteosarcoma. Patients with a disrupted copy of the RB1 gene are strongly sensitized to development of osteosarcoma (Friend et al., 1986) , RB being able to sequester and inactivate ID2 (Iavarone et al., 1994; Lasorella et al., 2000) . Our study reveals an additional mechanism by which ID proteins and, in turn, CDKIs can be dysregulated in osteosarcoma.
ID Proteins Modulate Osteogenic Development of Mesenchymal Precursors
Our data also implicate ID proteins in normal osteogenic development. ID2 or USP1 overexpression in mesenchymal stem cells See also Figure S6 .
inhibited osteogenic differentiation and promoted retention of mesenchymal stem cell features ( Figure 6 ). These findings support a recent study describing a role for ID proteins in mesenchymal differentiation (Peng et al., 2004) . Intriguingly, Id1/Id3 compound heterozygous mutant mice display calvarial defects and reduced osteoblast outgrowth (Maeda et al., 2004) , suggestive of a mesenchymal proliferation defect. It is unknown if additional Id2 deficiency would exacerbate this phenotype due to early lethality. Restricting Id gene deletion to the mesenchymal lineage may prove informative. The osteopenia that occurs in Usp1 À/À mice is consistent with the phenotype predicted by USP1 knockdown in osteosarcoma and USP1 overexpression in primary hMSCs (Figure 7 and Figure S6) . In each setting our data suggest the USP1-ID axis inhibits lineage commitment. An independent USP1-deficient mouse strain also demonstrated runting and perinatal lethality (Kim et al., 2009 ). Mice lacking multiple Id genes die early in embryogenesis (Lyden et al., 1999) , which could indicate that an additional DUB regulates ID protein stability in early development, or that other DUBs can compensate for the absence of USP1. Recent studies suggest that the bHLH proteins inhibited by IDs 1-3 during osteogenesis may belong to the Hey/Hes family. Hey1 overexpression promoted osteoblastic differentiation, whereas Hey1 knockdown inhibited it (Sharff et al., 2009 ). Similarly, Hes1 overexpression promoted osteocommitment (Suh et al., 2008) . It is possible that multiple bHLH transcription factors act in parallel to promote osteoblast development. USP1 and ID proteins would be positioned to broadly restrain bHLH-driven commitment signals engaged during differentiation of mesenchymal stem cells. We propose that USP1 belongs to an emerging set of caulo-oncogenes that promotes tumorigenesis through subversion of normal stem (Latin ''caulo'') cell biology.
A consequence of our findings, one that has significant therapeutic ramifications, is that inhibition of USP1 protease activity should institute a differentiation program in malignant osteosarcoma leading to a precipitous decline in proliferative capacity and potential reversal of the transformed phenotype. Targeting USP1 would be expected to impact all USP1 substrates including FANCD2, but this may be beneficial because defective DNA repair in tumor cells lacking a normal p53 checkpoint is predicted to sensitize them to crosslinking chemotherapeutic agents or PARP inhibitors (D'Andrea, 2010). Differentiation treatments for cancer, as evidenced by the spectacular success of arsenic as a differentiation therapy for acute promyelocytic leukemia, provide an exciting option for the effective treatment of previously lethal cancers. Targeting USP1 may provide such an opportunity for osteogenic sarcoma.
EXPERIMENTAL PROCEDURES
Cell Lines Human 143B, 293T, HOS, MG-63, SAOS-2, SJSA, and U2-OS cells, murine NIH 3T3 cells (ATCC), and primary human osteoblasts (PromoCell) were grown in DMEM with 10% FBS (Sigma-Aldrich), 10 U/ml penicillin, and 10 mg/ml streptomycin (GIBCO). Primary hMSCs derived from normal bone marrow were cultured in hMSC medium (Lonza) or osteogenic differentiation medium (Lonza) with 100 ng/ml BMP-9 (R&D Systems). Primary human osteosarcomas were from CytoMix, LLC, and the CHTN. DT-40 cells from K. Patel (MRC-LMB) were cultured in RPMI with 7% FBS and 3% chicken serum (GIBCO). Where indicated, cells were treated with 10 mM MG-132 (Calbiochem) or 25 mg/ml cycloheximide (Sigma-Aldrich). Complete experimental procedures are available in the Extended Experimental Procedures.
Vectors USP1 variants, ID1, ID2, and ID3 were in pRK2001 with or without a C-terminal Flag epitope. A WDR48 expression vector was from OriGene. pMACS was from Miltenyi Biotec. ID2 and USP1 variants also were subcloned into pQCXIP (Clontech) or pHUSH.Lenti.Puro (Genentech). Knockdown experiments used pRS-based shRNA vectors (OriGene) or the pTRIPZ shRNA system (Open Biosystems).
Transfections
Osteosarcoma cells were transfected with the plasmids indicated in combination with the marker plasmid pMACS using FuGENE 6 (Sigma-Aldrich Gene Expression RNA was extracted with RNeasy kits (QIAGEN) and amplified with the QuantiTect SYBR Green RT-PCR system (QIAGEN). Primary tumor RNA data were obtained from GeneLogic microarray analyses (Ocimum Biosolutions) with HGU133P Affymetrix chips.
Flow Cytometry
Cells staining with FITC-conjugated anti-H-2K k antibodies (Miltenyi Biotec) were stained with propidium iodide (Sigma-Aldrich) in the presence of RNase A (Sigma-Aldrich), and their DNA content was measured in a FACSCalibur flow cytometer (BD Biosciences). Other antibodies used recognized CD90 (Chemicon), CD105 (R&D Systems), CD106 (SouthernBiotech), and CD144 (eBioscience).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were incubated in target retrieval solution (Dako) at 99 C for 20 min and cooled to 74 C for 20 min.
Sections were blocked at room temperature in avidin/biotin blocking buffer (Vector Labs) and then 3% BSA for 30 min. Staining with primary antibody was at room temperature for 60 min. Sections were rinsed twice in Dako wash buffer and then incubated in VECTASTAIN reagents (Vector Labs) for 30 min. Staining was revealed with peroxidase substrate buffer (Pierce), then sections were counterstained with Mayer's Hematoxylin. TRAP staining (Sigma-Aldrich) was on 5 mm sections from formalin-fixed, paraffin-embedded P12 mouse femurs. TRAP-positive osteoclasts were counted in ten fields. Alizarin red staining was performed according to manufacturer instructions (Ricca Chemical).
Immunofluorescence Staining
Stably transduced U2-OS cells treated with 3 mg/ml doxycycline (Clontech) for 14 days were fixed in 1% PFA in PBS and stained with antibodies recognizing E-cadherin, N-cadherin (BD), or fibronectin (Calbiochem).
In Vivo Deubiquitination
Transfected 293T cells were cultured with 10 mM MG-132 for 30 min prior to extraction in lysis buffer containing 10 mM MG-132 and 10 mM N-ethylmaleimide (Sigma-Aldrich). Soluble lysates were denatured with 1% SDS at 95 C for 5 min, then diluted 20-fold in lysis buffer prior to immunoprecipitation with M2 anti-Flag agarose (Sigma-Aldrich).
In Vitro Deubiquitination 293T cells were transfected with USP1-Flag, USP1-C90S-Flag, or ID2-Flag and HA-ubiquitin. ID2-Flag was immunoprecipitated from SDS-denatured cell lysate. USP1 was immunoprecipitated from regular cell lysate. Elutions were with 500 mg/ml 3X Flag peptide (Sigma-Aldrich). Samples were combined in DUB buffer (20 mM HEPES [pH 8.3], 20 mM NaCl, 100 mg/ml BSA, 500 mM EDTA, 1 mM DTT) at room temperature.
Osteosarcoma Differentiation U2-OS, HOS, or SAOS cells transfected serially with pRS.shUSP1 (or shCTL) were selected based on H-2K k expression and cultured for 12 days. 143B cells transduced with pTRIPZ inducible USP1 shRNA were selected in puromycin. ALP activity was determined in cell lysates lacking phosphatase inhibitors after normalizing for protein content. p-nitrophenyl phosphatase cleavage was analyzed by colorimetric assay (Sigma-Aldrich).
3T3 Transformation
Transduced 3T3 cells were plated in DMEM/0.5% low-melting agar on 1% agar. Colonies of eight or more cells were scored visually after 21 days. For ID knockdown, USP1-expressing 3T3 cells were transduced with pTRIPZ inducible shRNAs and cultured with 3 mg/ml doxycycline for 72 hr prior to embedding in agar containing 3 mg/ml doxycycline.
Mice
Eight-week-old female NCr nude mice (Taconic) or C.B-17 SCID.bg mice (CRL) were injected subcutaneously in the right hind flank with 1 3 10 6 3T3 cells or 2.5 3 10 6 143B cells in 100 ml HBSS and provided 1 mg/ml doxycycline in 5% sucrose water. Usp1 gene-targeted C57BL/6 ES cells were from the Knockout Mouse Project Repository (Davis, CA). Microcomputed tomography was a mCT 40 (SCANCO Medical). Amniotic fluid from E18.5 embryos was assayed for deoxypyridinoline (TSZ ELISA), BALP (EIAab & USCNLIFE), and creatinine (R&D Systems). The Genentech Institutional Animal Care and Use Committee approved all animal studies.
ACCESSION NUMBERS
mRNA expression data of USP1 were extracted from the Gene Logic expression database of Affymetrix Human Genome U133 Plus 2.0 data. The probe set 202412_s_at was chosen to represent the expression of USP1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six figures, and one table and can be found with this article online at doi:10.1016/j.cell.2011.07.040.
